To investigate the influence of vasoconstrictor agents on MDCT features in patients with non-occlusive mesenteric ischemia (NOMI).
Key Findings:
NOMI accounts for 20-30% of acute bowel ischemia cases and has a mortality rate of 70-90%.
MDCT is preferred over DSA for initial NOMI diagnosis due to its spatial resolution and ability to show bowel signs.
Vasoconstrictor agents are associated with increased risk of NOMI and may influence MDCT findings, complicating diagnosis.
Interpretation:
The use of vasoconstrictor agents in critically ill patients may exacerbate vascular changes detectable by MDCT, complicating NOMI diagnosis and potentially worsening patient outcomes.
Limitations:
Single-center study may limit generalizability.
Retrospective design may introduce selection bias.
Potential confounding factors related to the use of vasoconstrictor agents were not fully explored.
Conclusion:
Early identification of NOMI using MDCT is crucial, especially in patients receiving vasoconstrictor therapy, to improve clinical outcomes.
International study of more than 19,000 patients finds substantial differences in radiation exposure from coronary artery disease imaging across modalities, regions, and income levels.
